We are dedicated to bringing the latest advances in tumor vaccines and immunotherapy to patients with cancer.
This goal is accomplished through clinical trials.
A clinical trial is an experimental study that tests the effects of a new agent (vaccine or drug) in patients with cancer.
Most tumor immunotherapy treatments are currently only available through clinical trials.
At Columbia, we conduct early Phase I studies of new agents through the National Cancer Institute, as well as Phase II and III clinical trials supported by pharmaceutical companies and the Southwest Oncology Group (SWOG), a national consortium of medical centers dedicated to bringing clinical trials to patients with all types of cancer.
Our staff includes a team of physicians, scientists, nurses, pharmacists, and social workers with expertise in the use of immunotherapy in patients with cancer.
Patients ordinarily need to meet certain medical requirements before enrolling in a clinical trial.
You or your medical oncologist can contact us to learn about eligibility requirements.
Participation is voluntary and you may withdraw at any time.
A list of our active trials follows, but we recommend calling to get the most up to date information on our clinical trials program.
For more information regarding participation in one of our trials please contact Maryann Vella, RN, OCN, Clinical Coordinator at 212.305.5676, firstname.lastname@example.org or
Amiya Vaz, CRC, Clinical Research Coordinator at 212.305.1317, email@example.com.
- A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients with BRAFV600 Mutation Positive Metastatic Melanoma
- Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy®) in Patients with Metastatic Melanoma
- A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon α-2b for Resected High-Risk Melanoma
- A multicentre, open label, randomized Phase II trial of the MEK inhibitor pimasertib or dacarbazine in previously untreated subjects with N-Ras mutated locally advanced or metastatic malignant cutaneous melanoma
- An Open-label, Multicenter, Phase II Study of Continuous Oral Vemurafenib in Patients with Locally Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
- A Randomized Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Treatment with OncoVEXGM-CSF Compared to Subcutaneously Administered GM-CSF in Melanoma Patients with Unresectable Stage IIIb, IIIc and IV Disease
- Tissue Banking: Consent to Participate as a Blood, Tissue and/or Biologic Fluid Donor
Renal Cell Trials
- A Preliminary Study of the Safety, Immunogenicity and Clinical Efficacy of TroVax given in conjunction with Interleukin-2 (IL-2) in the Treatment of Stage IV Renal Cell Cancer